Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Other 1NET 1Gastrointestinal 1CNS 1

Conditions

Pituitary Diseases 1Obesity 1Neoplasms 1Hyperinsulinism 1Craniopharyngioma 1

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 83Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diazoxide × CNS × Clear all
NCT00306683 2011-02-18

Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
40 enrolled
CNSEndocrineOther

Craniopharyngioma, Hyperinsulinism, Neoplasms, Obesity, Pituitary Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡